NewAmsterdam Pharma Co N.V. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on August 12, 2025, by NewAmsterdam Pharma Company N.V. (NAMS), a Netherlands-based biopharmaceutical company. The report details a material definitive agreement entered into on the same date.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual agreement rather than financial performance results.
Material Changes and Agreements
On August 12, 2025, NewAmsterdam Pharma B.V. (a subsidiary of the Company) entered into a Supply Agreement with A. Menarini International Licensing S.A. ("Menarini"). Key terms include:
- Scope: The subsidiary will supply Menarini with obicetrapib monotherapy and obicetrapib/ezetimibe fixed-dose combination finished products in bulk tablet form.
- Exclusivity: The subsidiary will initially serve as Menarini's exclusive supplier for these products.
- Pricing: Pricing is based on a specified mark-up to the subsidiary's cost of goods sold, subject to periodic adjustments.
- Manufacturing Transfer: The parties will initiate a process to transfer manufacturing to Menarini or a designated third-party contract manufacturer. The subsidiary granted Menarini a non-exclusive license under the Company's patents and know-how for this purpose.
- Term and Termination: The agreement lasts for the duration of the underlying License Agreement (dated June 23, 2022). The subsidiary may terminate for convenience with 120 days' notice, provided termination occurs after the manufacturing transfer is complete or two years after its initiation.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or management commentary on future earnings. The primary risk noted is the potential for termination due to uncured material breaches, insolvency, or force majeure events lasting six months or longer. The full text of the Supply Agreement is intended to be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ending September 30, 2025.
Investor Verification Checklist
- Verify the specific mark-up percentage applied to the cost of goods sold in the Supply Agreement.
- Confirm the timeline and milestones for the manufacturing transfer to Menarini or a third party.
- Review the binding volume forecast requirements Menarini must provide.
- Monitor the upcoming Form 10-Q filing for the full text of the Supply Agreement exhibit.